TNF and rheumatoid arthritis: Infliximab and adalimumab, the first FDA-approved anti-TNF-α agents, have been used in various rheumatic and dermatologic disorders, such as rheumatoid arthritis (RA), psoriasis, psoriatic arthritis (PsA), and ankylosing spondylitis (AS), for over two decades with proven efficacy and safety [9].